文献速递肿瘤 PET/CT

[68Ga]Ga-FAPI-04与[18F]FDG PET/CT在胰腺癌诊断与分期中的头对头前瞻性研究

Head to head comparison of [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT in the diagnosis and staging of pancreatic cancer: a prospective study.
PubMed 文献 · EJNMMI Res · 2026-06-05

这项前瞻性单中心研究纳入97例疑似胰腺癌患者(最终88例确诊),头对头比较[68Ga]Ga-FAPI-04与[18F]FDG PET/CT的诊断效能。FAPI-04在原发灶、淋巴结及骨/内脏转移灶的SUVmax和靶本比均显著更高,AUC更优,并修正了7例分期、改变了6例治疗决策。

要点

  • FAPI-04在原发灶和淋巴结转移的SUVmax及AUC均显著优于FDG。
  • FAPI-04对骨、肝、腹膜等转移灶的靶本比和AUC更高。
  • FAPI-04使分期准确率提高至93.2%,并改变6例手术决策。

核心结论

  • [68Ga]Ga-FAPI-04 PET/CT在胰腺癌诊断效能上可能优于[18F]FDG PET/CT,并改善分期与临床决策。

研究设计与样本

  • 前瞻性单中心研究,纳入97例疑似胰腺癌患者(58例男性,平均年龄63.0±10.1岁),最终88例确诊为胰腺癌(57例经病理、31例经影像随访)。

主要发现

  • FAPI-04在原发灶的SUVmax为10.2±3.5(95%CI:9.320-11.126),高于FDG的6.1±3.8(95%CI:5.092-7.152),p=0.001。
  • FAPI-04在淋巴结转移的SUVmax为4.1±2.4(95%CI:3.718-4.559),高于FDG的3.3±2.3(95%CI:2.845-3.714),p=0.001。
  • FAPI-04在原发灶和淋巴结的AUC分别为0.851(95%CI:0.735-0.981)和0.867(95%CI:0.827-0.907),均对应p=0.001。
  • FAPI-04在骨和内脏转移的靶本比为4.7±3.1(95%CI:4.108-5.245),高于FDG的2.5±1.6(95%CI:2.231-2.835),p=0.001。
  • FAPI-04的分期准确率为93.2%,高于FDG的72.7%,p=0.007,并修正7例分期、改变6例治疗决策(手术切除改为不可切除)。

关键数值与推荐

  • FAPI-04的SUVmax是原发灶的阳性预测因子(OR=1.951,95%CI:1.286-2.960,p=0.004)。
  • FAPI-04的SUVmax(OR=4.199,95%CI:2.970-5.939,p=0.001)和TBR(OR=14.502,95%CI:7.228-29.095,p=0.001)是淋巴结转移的阳性预测因子。
  • 对骨和内脏转移,FAPI-04的SUVmax(OR=2.925,95%CI:2.048-4.177,p=0.003)和T/B比(OR=3.520,95%CI:2.311-5.362,p=0.001)优于FDG(SUVmax:OR=1.901,95%CI:1.308-2.761,p=0.003;T/B比:OR=2.480,95%CI:1.488-4.136,p=0.001)。

临床怎么用

  • 对疑似或确诊胰腺癌患者,FAPI-04 PET/CT可提供更高的原发灶、淋巴结及远处转移检出效能,有助于更准确分期和制定治疗决策。

局限性

  • 单中心研究、随访时间短、部分亚组(如复发病灶)样本量小,且部分病例未获完整病理确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: [68Ga]Ga-FAPI-04 targets FAP overexpressed in pancreatic cancer microenvironment. This study compared diagnostic efficacy and clinical impact with [18F]FDG PET/CT in pancreatic cancer. RESULTS: Of 97 suspected pancreatic cancer patients (58 males; mean age 63.0 ± 10.1 years), 88 were confirmed as pancreatic cancer (57 by pathology, 31 by imaging follow‑up). [68Ga]Ga-FAPI-04 PET/CT showed significantly higher SUVmax than [18F]FDG PET/CT in primary lesions (10.2 ± 3.5, 95%CI: 9.320-11.126 vs. 6.1 ± 3.8, 95%CI: 5.092-7.152; p = 0.001) and lymph node metastases (4.1 ± 2.4, 95%CI: 3.718-4.559 vs. 3.3 ± 2.3, 95%CI: 2.845-3.714; p = 0.001), with superior AUCs for primary tumors and lymph nodes(0.851, 95% CI: 0.735-0.981 vs. 0.802, 95% CI: 0.354-0.803; p = 0.001) (0.867, 95% CI: 0.827-0.907 vs. 0.701, 95% CI: 0.641-0.761; p = 0.001). The T/B ratio of bone and visceral metastases was higher in [68Ga]Ga-FAPI-04 PET/CT than [18F]FDG PET/CT(4.7 ± 3.1, 95%CI: 4.108-5.245 vs. 2.5 ± 1.6, 95%CI: 2.231-2.835; p = 0.001) with superior AUC(0.938, 95% CI: 0.912-0.964 vs. 0.919, 95% CI: 0.886-0.951; p = 0.040), as were liver (5.0 ± 4.0, 95%CI: 3.706-6.284 vs. 2.7 ± 1.3, 95%CI: 2.211-3.131; p = 0.001), peritoneal (5.4 ± 3.3, 95%CI: 4.318-6.482 vs. 3.0 ± 2.1. 95%CI: 2.211-3.745; p = 0.001) and other organ metastases (4.4 ± 2.5, 95%CI: 3.756-5.035 vs. 2.7 ± 1.7, 95%CI: 1.379-2.254; p = 0.001). [68Ga]Ga‑FAPI‑04 SUVmax and TBR were positive predictors for primary tumors (SUVmax: OR = 1.951, 95%CI: 1.286-2.960, p = 0.004) and nodal metastases (SUVmax: OR = 4.199, 95%CI: 2.970-5.939, p = 0.001; TBR: OR = 14.502, 95%CI: 7.228-29.095, p = 0.001). For bone and visceral metastases, both tracers were positive predictors, but [68Ga]Ga‑FAPI‑04 SUVmax (OR = 2.925, 95%CI: 2.048-4.177, p = 0.003) and T/B ratio (OR = 3.520, 95%CI: 2.311-5.362, p = 0.001) outperformed [18F]FDG (SUVmax: OR = 1.901, 95%CI: 1.308-2.761, p = 0.003; T/B ratio: OR = 2.480, 95%CI: 1.488-4.136, p = 0.001). Furthermore, [68Ga]Ga-FAPI-04 achieved higher accuracy (93.2% vs. 72.7%, p = 0.007), revised the staging of 7 patients and altered the treatment (surgical resection to unresectable) in 6 patients. Limitations include single‑center, short follow‑up, small subgroups (e.g., recurrent lesions) and incomplete pathologically confirmation. CONCLUSION: [68Ga]Ga-FAPI-04 PET/CT suggested potentially better diagnostic performance to [18F]FDG PET/CT and improves staging and clinical decision-making in pancreatic cancer, suggesting potential clinical value.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Yang R, Sun Y, An R, et al. Head to head comparison of [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT in the diagnosis and staging of pancreatic cancer: a prospective study. EJNMMI Res. 2026. PMID: 42249240. doi:10.1186/s13550-026-01456-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。